Aggrecan (E8B8S) Rabbit mAb #28971
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 600 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Aggrecan (E8B8S) Rabbit mAb recognizes endogenous levels of total aggrecan protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro1743 of human aggrecan protein.
Background
Aggrecan (AGC1, CSPG1, MSK16), encoded by the ACAN gene, is a large chondroitin sulfate proteoglycan and a major component of the extracellular matrix (ECM) in the growth plate and articular cartilage (1). There the protein forms a hydrated gel structure via its interaction with hyaluronan and a link protein, endowing the cartilage with load-bearing properties. Aggrecan is crucial in chondroskeletal morphogenesis during development (2). Aggrecan is also found in brain, heart, and aorta, where it is involved in the development and normal function of these tissues (3-5). Aggrecan has 3 globular domains G1, G2, and G3. The N-terminal G1 domain directly interacts with ECM hyaluronan to form large aggregates and a gel like structure. The G3 domain interacts with a variety of ECM molecules, such as tenascins, fibulins, and fibrillin, to mediate ECM structure and function. Many chondroitin sulfate chains (CS) and keratan sulfate chains (KS) are covalently attached to sites in the region between G2 and G3 of aggrecan. The CS- and KS- rich region forms a structure to provide binding and storage sites for growth factors such as VEGF and TGFβ. Mutation of aggrecan is associated with many disease phenotypes, such as short stature and abnormal skeletal structure formation (6,7). Aberrant high degradation of aggrecan by ADAMTS4 and ADAMTS5 is a key process during osteoarthritis (8,9).
- Watanabe, H. et al. (1998) J Biochem 124, 687-93.
- Kiani, C. et al. (2002) Cell Res 12, 19-32.
- Rambeau, P. et al. (2017) Int J Cardiol 249, 340-343.
- Rowlands, D. et al. (2018) J Neurosci 38, 10102-10113.
- Koch, C.D. et al. (2020) J Histochem Cytochem 68, 777-795.
- Dateki, S. (2017) Clin Pediatr Endocrinol 26, 119-125.
- Gibson, B.G. and Briggs, M.D. (2016) Orphanet J Rare Dis 11, 86.
- Verma, P. and Dalal, K. (2011) J Cell Biochem 112, 3507-14.
- Roughley, P.J. and Mort, J.S. (2014) J Exp Orthop 1, 8.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.